Total Payments
$3,391
2024 Payments
$3,101
Companies
9
Transactions
15
Medicare Patients
372
Medicare Billing
$47,695
Payment Breakdown by Category
Consulting$2,220 (65.5%)
Food & Beverage$1,171 (34.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,220 | 2 | 65.5% |
| Food and Beverage | $1,171 | 13 | 34.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,220 | 2 | $0 (2024) |
| Exelixis Inc. | $391.50 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $246.99 | 2 | $0 (2024) |
| Aveo Pharmaceuticals, Inc. | $168.03 | 2 | $0 (2024) |
| Fennec Pharmaceuticals, Inc. | $134.21 | 1 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $104.57 | 1 | $0 (2024) |
| Eisai Inc. | $76.84 | 1 | $0 (2023) |
| Astellas Pharma US Inc | $29.25 | 2 | $0 (2023) |
| Boston Scientific Corporation | $19.30 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,101 | 9 | E.R. Squibb & Sons, L.L.C. ($2,220) |
| 2023 | $270.68 | 5 | AstraZeneca Pharmaceuticals LP ($131.37) |
| 2022 | $19.30 | 1 | Boston Scientific Corporation ($19.30) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $104.57 | General |
| Category: Oncology | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 11/11/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $134.81 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $145.83 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 10/23/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $120.85 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/25/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $134.21 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 01/27/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $115.62 | General |
| Category: Oncology | ||||||
| 01/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $124.82 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/18/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $131.37 | General |
| Category: Oncology | ||||||
| 08/31/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Oncology | ||||||
| 08/31/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: Oncology | ||||||
| 08/23/2023 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $76.84 | General |
| 08/07/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $33.22 | General |
| Category: Oncology | ||||||
| 10/27/2022 | Boston Scientific Corporation | JETSTREAM SC (Device) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: JETSTREAM_PI | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 336 | 549 | $334,648 | $44,266 |
| 2022 | 3 | 36 | 68 | $4,385 | $3,429 |
Total Patients
372
Total Services
617
Medicare Billing
$47,695
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 73 | $70,080 | $11,265 | 16.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 40 | 40 | $54,400 | $7,538 | 13.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $46,655 | $6,150 | 13.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 45 | $38,610 | $4,971 | 12.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 48 | $32,640 | $4,785 | 14.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 25 | 49 | $19,915 | $2,884 | 14.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 13 | 22 | $25,441 | $2,659 | 10.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $17,160 | $1,889 | 11.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 15 | 40 | $19,000 | $1,050 | 5.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 37 | 51 | $2,958 | $388.11 | 13.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 12 | 14 | $2,449 | $380.10 | 15.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 12 | 18 | $4,410 | $251.65 | 5.7% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 27 | 62 | $620.00 | $31.20 | 5.0% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 12 | 31 | $310.00 | $23.65 | 7.6% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 12 | 44 | $2,761 | $2,146 | 77.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 12 | 12 | $1,320 | $1,043 | 79.0% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2022 | 12 | 12 | $304.08 | $240.19 | 79.0% |
About Adam Singer
Adam Singer is a Hematology & Oncology healthcare provider based in Torrance, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/24/2017. The National Provider Identifier (NPI) number assigned to this provider is 1770014326.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Adam Singer has received a total of $3,391 in payments from pharmaceutical and medical device companies, with $3,101 received in 2024. These payments were reported across 15 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($2,220).
As a Medicare-enrolled provider, Singer has provided services to 372 Medicare beneficiaries, totaling 617 services with total Medicare billing of $47,695. Data is available for 2 years (2022–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Torrance, CA
- Active Since 03/24/2017
- Last Updated 07/18/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1770014326
Products in Payments
- CABOMETYX (Drug) $391.50
- LYNPARZA (Drug) $246.99
- FOTIVDA (Drug) $168.03
- Pedmark (Drug) $134.21
- ERLEADA (Drug) $104.57
- Padcev (Drug) $29.25
- JETSTREAM SC (Device) $19.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Torrance
Rowan Chlebowski, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $289,631
Hematology & Oncology $289,631
Amy Cummings
Hematology & Oncology — Payments: $107,686
Hematology & Oncology $107,686
Dr. Michael Chung, M.d, M.D
Hematology & Oncology — Payments: $37,900
Hematology & Oncology $37,900
Dr. Sarah Tomassetti, M.d, M.D
Hematology & Oncology — Payments: $37,860
Hematology & Oncology $37,860
Aileen Novero, M.d, M.D
Hematology & Oncology — Payments: $9,932
Hematology & Oncology $9,932
Jennifer Lee, M.d, M.D
Hematology & Oncology — Payments: $6,983
Hematology & Oncology $6,983